JP2015517982A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517982A5 JP2015517982A5 JP2014560096A JP2014560096A JP2015517982A5 JP 2015517982 A5 JP2015517982 A5 JP 2015517982A5 JP 2014560096 A JP2014560096 A JP 2014560096A JP 2014560096 A JP2014560096 A JP 2014560096A JP 2015517982 A5 JP2015517982 A5 JP 2015517982A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- binding fragment
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 20
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 19
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 19
- 150000001413 amino acids Chemical group 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000012545 EGF-like domains Human genes 0.000 claims description 4
- 108050002150 EGF-like domains Proteins 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims 19
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 9
- 210000005102 tumor initiating cell Anatomy 0.000 claims 6
- 230000005907 cancer growth Effects 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 3
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 2
- 102220467332 Protein BEX4_L94A_mutation Human genes 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102220527485 Calcium-activated potassium channel subunit beta-4_N90A_mutation Human genes 0.000 description 1
- 102220604032 Clathrin heavy chain 1_Q89A_mutation Human genes 0.000 description 1
- 102220575490 Glutamate receptor ionotropic, NMDA 2A_D96A_mutation Human genes 0.000 description 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 1
- 102220498733 Interleukin-6 receptor subunit alpha_N55A_mutation Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 102220512015 Synaptotagmin-7_Q54A_mutation Human genes 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 102000045551 human EPCAM Human genes 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102200062292 rs1114167623 Human genes 0.000 description 1
- 102220020162 rs397508045 Human genes 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606220P | 2012-03-02 | 2012-03-02 | |
| US61/606,220 | 2012-03-02 | ||
| PCT/US2013/028667 WO2013131001A1 (en) | 2012-03-02 | 2013-03-01 | ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517982A JP2015517982A (ja) | 2015-06-25 |
| JP2015517982A5 true JP2015517982A5 (OSRAM) | 2016-06-23 |
| JP6163502B2 JP6163502B2 (ja) | 2017-07-12 |
Family
ID=49083343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014560096A Active JP6163502B2 (ja) | 2012-03-02 | 2013-03-01 | 抗上皮細胞接着分子（ＥｐＣＡＭ）抗体及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9187558B2 (OSRAM) |
| EP (1) | EP2819695B1 (OSRAM) |
| JP (1) | JP6163502B2 (OSRAM) |
| CN (1) | CN104168916B (OSRAM) |
| TW (1) | TWI485161B (OSRAM) |
| WO (1) | WO2013131001A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013003624A2 (en) | 2011-06-29 | 2013-01-03 | Academia Sinica | The capture, purification and release of biological substance using a surface coating |
| EP3126814B1 (en) | 2014-04-01 | 2019-06-12 | Academia Sinica | Methods and systems for cancer diagnosis and prognosis |
| US11098131B2 (en) | 2015-07-31 | 2021-08-24 | Sutro Biopharma, Inc. | Anti-EpCAM antibodies, compositions comprising anti-EpCAM antibodies and methods of making and using anti-EpCAM antibodies |
| ES2873846T5 (en) * | 2015-11-19 | 2025-06-23 | Revitope Ltd | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| US10107726B2 (en) | 2016-03-16 | 2018-10-23 | Cellmax, Ltd. | Collection of suspended cells using a transferable membrane |
| AU2017301826A1 (en) | 2016-07-26 | 2019-03-14 | Tessa Therapeutics Ltd. | Chimeric antigen receptor |
| JP6433951B2 (ja) * | 2016-08-09 | 2018-12-05 | 東芝デジタルソリューションズ株式会社 | ネットワーク監視装置およびプログラム |
| US10787499B2 (en) | 2017-02-13 | 2020-09-29 | Regents Of The University Of Minnesota | EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| WO2020051141A1 (en) * | 2018-09-04 | 2020-03-12 | Academia Sinica | A medium composition and method for culturing mesenchymal stem cells |
| CN119954959A (zh) * | 2019-03-11 | 2025-05-09 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
| JP7387196B2 (ja) * | 2019-06-11 | 2023-11-28 | バイオアトラ インコーポレイテッド | 条件付きで活性な抗ｅｐｃａｍ抗体、抗体フラグメント、それらのイムノコンジュゲート、及びそれらの使用 |
| EP4058478A4 (en) * | 2019-11-14 | 2022-12-28 | Academia Sinica | USES OF ANTI-EPCAM ANTIBODIES IN CANCER THERAPY |
| CN110950959B (zh) * | 2020-02-25 | 2020-07-03 | 和铂医药(上海)有限责任公司 | 靶向EpCAM的抗体及其制备和应用 |
| CN112094350B (zh) * | 2020-06-01 | 2024-01-05 | 普众发现医药科技(上海)有限公司 | 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体 |
| US20230357427A1 (en) * | 2020-08-19 | 2023-11-09 | Shanghai Immunohead Biotechnology Co., Ltd | Humanized antibody, chimeric antigen receptor, nucleic acid, vector, cell and use |
| KR20230125808A (ko) * | 2020-12-18 | 2023-08-29 | 바이오아르디스 엘엘씨 | EpCAM 결합 분자 및 이의 사용 |
| TWI754504B (zh) * | 2020-12-25 | 2022-02-01 | 龍華科技大學 | 棉花棒棒體之膠體檢測系統及其檢測方法 |
| US20250269018A1 (en) * | 2021-06-25 | 2025-08-28 | Academia Sinica | Combined cancer therapy with an epithelial cell adhesion molecule (epcam) inhibitor and a hepatocyte growth factor receptor (hgfr) inhibitor |
| JP2024527524A (ja) * | 2021-06-25 | 2024-07-25 | アカデミア シニカ | 上皮細胞接着分子（ｅｐｃａｍ）阻害剤およびｗｎｔ阻害剤の併用癌治療法 |
| JP2023069350A (ja) * | 2021-11-05 | 2023-05-18 | シスメックス株式会社 | 抗体の製造方法及び抗体 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69800716T2 (de) * | 1997-04-14 | 2001-09-20 | Micromet Gesellschaft Fuer Biomedizinische Forschung Mbh | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen |
| DE60035434T2 (de) * | 1999-12-27 | 2008-05-15 | Crucell Holland B.V. | Auswahl von epitop-bindungsfähigen verbindungen aus bibliotheken |
| MXPA03009924A (es) * | 2001-05-03 | 2004-01-29 | Merck Patent Gmbh | Anticuerpo recombinante especifico de tumor y uso del mismo. |
| US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
| US7696320B2 (en) * | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP1629275A2 (de) | 2003-06-02 | 2006-03-01 | Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG | Verfahren zur selektion von epitopen zur immuntherapie |
| US20050180979A1 (en) * | 2004-02-13 | 2005-08-18 | Micromet Ag | Anti-EpCAM immunoglobulins |
| CA2652434A1 (en) * | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized proteins that target ep-cam |
| US7521195B1 (en) * | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
| JP5631733B2 (ja) * | 2007-04-04 | 2014-11-26 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ | 抗ＥｐＣＡＭ抗体およびその使用 |
| JP2011193728A (ja) * | 2008-07-17 | 2011-10-06 | Murata Mfg Co Ltd | ＥｐＣＡＭに結合能を有するペプチド |
| GB0909904D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| EP2480687B1 (en) * | 2009-09-21 | 2015-01-28 | Paul Walfish | Methods and compositions for the diagnosis and treatment of thyroid cancer |
| TW201125583A (en) * | 2009-12-23 | 2011-08-01 | Bioalliance Cv | Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same |
| EP2567235B1 (en) * | 2010-05-04 | 2017-08-30 | Paul Walfish | Method for the diagnosis of epithelial cancers by the detection of epicd polypeptide |
-
2013
- 2013-03-01 JP JP2014560096A patent/JP6163502B2/ja active Active
- 2013-03-01 US US14/381,362 patent/US9187558B2/en active Active
- 2013-03-01 EP EP13754991.1A patent/EP2819695B1/en active Active
- 2013-03-01 WO PCT/US2013/028667 patent/WO2013131001A1/en not_active Ceased
- 2013-03-01 CN CN201380012187.0A patent/CN104168916B/zh active Active
- 2013-03-01 TW TW102107344A patent/TWI485161B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517982A5 (OSRAM) | ||
| CN112154157B (zh) | 抗ror1抗体及其用途 | |
| CN108026169B (zh) | 抗人cd137的完全人抗体及其应用 | |
| JP6239503B2 (ja) | 新規な抗ｃｘｃｒ４抗体並びに癌の検出および診断のためのその使用 | |
| JP2019511904A5 (OSRAM) | ||
| CN112010978B (zh) | TrkA的抗体及其应用 | |
| US10809263B2 (en) | Antigenic composition for detecting auto-antibody with specific response to exosomal protein EIF3A, and method for diagnosing liver cancer using antigenic composition | |
| Gellini et al. | Generation of human single-chain antibody to the CD99 cell surface determinant specifically recognizing Ewing’s sarcoma tumor cells | |
| US20230287128A1 (en) | Antigen-binding proteins targeting kklc-1 shared antigen | |
| JP6707660B2 (ja) | 抗ポドカリキシン様タンパク質前駆体サブタイプ２モノクローナル抗体とその生成方法及び使用 | |
| WO2023025315A1 (zh) | 抗b7-h3抗体、其制备方法及用途 | |
| JP6977105B2 (ja) | Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用 | |
| KR20210126057A (ko) | 암세포에 존재하는 케라틴 14(krt14)의 세포외 부분을 표적화함으로써 암을 치료하거나 예방하는 방법 | |
| AU2022223337A1 (en) | Vegfa-binding molecules | |
| WO2019066617A2 (ko) | 항 c-met 항체 및 이의 용도 | |
| JP7229503B2 (ja) | ＣＡＤＭ１ｖ９認識抗体 | |
| CN106957367B (zh) | 抗idh1 r132h抗体及其制备方法和用途 | |
| JP7086607B2 (ja) | Ｉｇｆ－１ｒ抗体および癌の診断のためのその使用 | |
| TW202246321A (zh) | 抗pt217 tau抗體 | |
| CN106749661B (zh) | 抗psmp的单克隆抗体及其用途 | |
| KR102688094B1 (ko) | Cobll1 단백질 특이 항체 또는 이의 항원 결합 단편, 및 이의 용도 | |
| CN112079928B (zh) | 一种抗pd-l1的单克隆抗体 | |
| JP2014516922A (ja) | プレキシンｂ２活性の変調剤 | |
| CN117157401A (zh) | 针对胰腺癌干细胞的抗体 |